Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nutra PharmaNPHC Debt-to-Equity is -0.58 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 815 Drug Manufacturers companies, Nutra Pharma ranks worse than 122699.26% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nutra Pharma's Debt-to-Equity or its related term are showing as below:
NPHC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.72 Med: -0.59 Max: -0.24
Current: -0.58
During the past 13 years, the highest Debt-to-Equity Ratio of Nutra Pharma was -0.24. The lowest was -0.72. And the median was -0.59.
NPHC's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28
vs NPHC: -0.58
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nutra Pharma Debt-to-Equity Related Terms
Nutra Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nutra Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPHC vs UPC, CBIH, SXTC: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutra Pharma Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutra Pharma (NPHC) has a Debt-to-Equity of -0.58 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nutra Pharma and its competitors. According to the industry distribution chart, Nutra Pharma ranks #999999 out of 815 companies in the Drug Manufacturers industry.
Is Nutra Pharma's Debt-to-Equity too high?
Nutra Pharma's current Debt-to-Equity is -0.58. Based on the distribution chart, Nutra Pharma ranks #999999 out of 815 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Nutra Pharma's Debt-to-Equity compare to UPC and CBIH?
According to the Drug Manufacturers industry distribution chart, Nutra Pharma ranks #999999 out of 815 companies for Debt-to-Equity. This places Nutra Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nutra Pharma and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutra Pharma's current Debt-to-Equity is -0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutra Pharma stock overvalued right now?
Nutra Pharma (NPHC) has a current Debt-to-Equity of -0.58. The current Debt-to-Equity is -0.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nutra Pharma (NPHC), the current Debt-to-Equity is -0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPHC has been successfully added to your 
